Skip to content
Screener

Tarsus Pharmaceuticals, Inc. TARS Business Segments — Total revenues

Similar metrics at other companies

Intuitive Machines, Inc. logo
LUNRReportable Segment — Total revenues
$186.73M+199%
Sonida Senior Living logo
SNDAReportable Segment — Total revenues
$110.12M+38.9%
LanzaTech Global, Inc. logo
LNZAReportable Segment — Total revenues
$12.02M+26.8%
BGC Group, Inc. logo
BGCReportable Segment — Total revenues
$955.48M+43.8%
Alignment Healthcare logo
ALHCReportable Segment — Total revenues
$1.24B+33.3%
Trinet Group logo
TNETReportable Segment — Total revenues
$1.23B-5.1%

Other financials

Income statement

See full
Revenue$173.9M+69.4%
Gross profit$161.8M+67.8%
Operating income-$19.9M+10.3%
Net income-$18.6M+8.8%
EPS (diluted)-$0.43+10.4%

Balance sheet

See full
Cash & equivalents$206.6M+108%
Total debt$88.8M+22.6%
Total equity$346.7M+4.2%
Total assets$611.1M+23.5%

Cash flow

See full
Operating cash flow$61.2M+308%
CapEx$4.1M+306%
Free cash flow$57.2M+288%

Valuation

See full
Market cap$2.87B+63.9%
Enterprise value$2.75B+59.6%
P/S4.7×-1.2×

Profitability

See full
Gross margin79.8%
Operating margin-8%-3.5pp
Net margin-7.7%-3.3pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-13.7%-4.9pp
Debt / equity0.3×0.0×
Current ratio3.2×-2.1×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:25 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001819790-26-000064
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues:
Product sales, net$173,912$102,660$319,299$180,995
License fees and collaboration revenue16,667
Total revenues173,912102,660335,966180,995
Operating expenses:
Cost of sales12,1136,23721,50911,448
Research and development31,01015,59453,36130,003
Selling and marketing90,00265,857174,484126,143

Item 1. Financial Statements

FAQ

What is Tarsus Pharmaceuticals, Inc.'s business segments — total revenues?
Tarsus Pharmaceuticals, Inc. (TARS) reported business segments — total revenues of $173.91M in Q2 2026.
How has Tarsus Pharmaceuticals, Inc.'s business segments — total revenues changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s business segments — total revenues increased by 69.4% year-over-year, from $102.66M to $173.91M.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s business segments — total revenues?
Over 3 years (2022 to 2025), Tarsus Pharmaceuticals, Inc.'s business segments — total revenues has grown at a 159.5% compound annual growth rate (CAGR), from $25.82M to $451.36M.
What does business segments — total revenues mean?
Represents the total gross inflow of economic benefits arising from the ordinary operating activities of the business segment. This metric reflects the market demand and commercial success of the company's therapeutic products within its primary reportable segment.

Ask your AI about Tarsus Pharmaceuticals, Inc.'s business segments — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude